CYP3A4 and COVID-19: LPV/RTV, the current first-line antiretroviral drugs for HIV treatment, presented an antiviral effect against respiratory syndrome coronavirus two and have shown efficacy in COVID-19 patients (Cao et al., 2020); both are metabolized by CYP3A4 (Choy et al., 2020; Nutho et al., 2020).